• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
IMAGINE Network's ind nd ut nteractions ohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome.想象网络的行业交互队列(MAGIC)研究:炎症性肠病和肠易激综合征的前瞻性观察性多中心队列研究方案。
BMJ Open. 2020 Oct 21;10(10):e041733. doi: 10.1136/bmjopen-2020-041733.
2
Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome.卑尔根脑-肠-微生物群轴研究的研究方案:一项前瞻性病例报告特征分析和饮食干预研究,以评估微生物群改变对肠易激综合征患者认知以及大脑解剖和功能连接性的影响。
Medicine (Baltimore). 2020 Sep 11;99(37):e21950. doi: 10.1097/MD.0000000000021950.
3
Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.炎症性肠病患者出现真正的肠易激综合征样症状对心理健康和生活质量的负面影响。
Clin Gastroenterol Hepatol. 2017 Mar;15(3):376-384.e5. doi: 10.1016/j.cgh.2016.05.012. Epub 2016 May 14.
4
Does symptom activity explain psychological differences in patients with irritable bowel syndrome and inflammatory bowel disease? Results from a multi-center cross-sectional study.症状活动是否可以解释肠易激综合征和炎症性肠病患者的心理差异?一项多中心横断面研究的结果。
J Psychosom Res. 2019 Nov;126:109836. doi: 10.1016/j.jpsychores.2019.109836. Epub 2019 Sep 13.
5
Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.炎症性肠病-肠易激综合征在CCFA合作伙伴中对患者报告结局的患病率及影响
Inflamm Bowel Dis. 2017 Feb;23(2):325-331. doi: 10.1097/MIB.0000000000001017.
6
I am doing the best that I can!: Living with inflammatory bowel disease and/or irritable bowel syndrome (part II).我已竭尽全力!:与炎症性肠病和/或肠易激综合征共处(第二部分)
Clin Nurse Spec. 2008 Nov-Dec;22(6):278-85. doi: 10.1097/01.NUR.0000325382.99717.ac.
7
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders.健康、憩室病、肠易激综合征及炎症性肠病中的肠道微生物群:是时候寻找胃肠道疾病的微生物标志物了。
Dig Dis. 2018;36(1):56-65. doi: 10.1159/000477205. Epub 2017 Jul 7.
8
The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?曼尼托巴炎症性肠病队列研究:诊断前的长期症状——肠易激综合征占多少比例?
Clin Gastroenterol Hepatol. 2006 May;4(5):614-20. doi: 10.1016/j.cgh.2006.03.003. Epub 2006 Apr 17.
9
Bugs and Brains, the Gut and Mental Health Study: a mixed-methods study investigating microbiota composition and function in anxiety, depression and irritable bowel syndrome.肠道与大脑、肠道与心理健康研究:一项混合方法研究,旨在调查焦虑、抑郁和肠易激综合征患者的微生物群落组成和功能。
BMJ Open. 2021 Mar 15;11(3):e043221. doi: 10.1136/bmjopen-2020-043221.
10
Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.炎症性肠病和肠易激综合征的肠道微生物组成和功能变化。
Sci Transl Med. 2018 Dec 19;10(472). doi: 10.1126/scitranslmed.aap8914.

引用本文的文献

1
Perspectives on the sustained engagement with digital health tools: protocol for a qualitative interview study among people living with Inflammatory Bowel Disease or irritable bowel syndrome.对持续使用数字健康工具的看法:一项针对炎症性肠病或肠易激综合征患者的定性访谈研究的方案。
BMJ Open. 2024 Nov 9;14(11):e089220. doi: 10.1136/bmjopen-2024-089220.
2
Ten health policy challenges for the next 10 years.未来十年的十大卫生政策挑战。
Health Aff Sch. 2023 Jun 20;1(1):qxad010. doi: 10.1093/haschl/qxad010. eCollection 2023 Jul.
3
Measuring the Impact of Patient Engagement in Health Research: An Exploratory Study Using Multiple Survey Tools.衡量患者参与健康研究的影响:一项使用多种调查工具的探索性研究。
J Can Assoc Gastroenterol. 2023 Dec 2;7(2):177-187. doi: 10.1093/jcag/gwad045. eCollection 2024 Apr.
4
Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.溃疡性结肠炎活动期治疗及粪便微生物群移植的患者偏好
Ther Adv Chronic Dis. 2024 Mar 26;15:20406223241239168. doi: 10.1177/20406223241239168. eCollection 2024.
5
Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study.克罗恩病的表型及其与合并症、手术风险、药物治疗和非药物治疗方法的关联:IMAGINE研究中的MAGIC研究
Inflamm Bowel Dis. 2025 Jan 6;31(1):113-122. doi: 10.1093/ibd/izae055.
6
Studying How Patient Engagement Influences Research: A Mixed Methods Study.研究患者参与如何影响研究:一项混合方法研究。
Patient. 2024 Jul;17(4):379-395. doi: 10.1007/s40271-024-00685-8. Epub 2024 Mar 15.
7
Exploring the outcomes of research engagement using the observation method in an online setting.探索在在线环境中使用观察法进行研究参与的结果。
BMJ Open. 2023 Nov 21;13(11):e073953. doi: 10.1136/bmjopen-2023-073953.
8
A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease.一项针对炎症性肠病的多成分在线减压干预的随机对照试验。
Therap Adv Gastroenterol. 2022 Sep 27;15:17562848221127238. doi: 10.1177/17562848221127238. eCollection 2022.
9
Dietary Fibre Intervention for Gut Microbiota, Sleep, and Mental Health in Adults with Irritable Bowel Syndrome: A Scoping Review.膳食纤维干预对肠易激综合征成人肠道微生物群、睡眠和心理健康的影响:系统评价。
Nutrients. 2021 Jun 23;13(7):2159. doi: 10.3390/nu13072159.

本文引用的文献

1
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.全球功能性胃肠病的流行情况和负担:罗马基金会全球研究结果。
Gastroenterology. 2021 Jan;160(1):99-114.e3. doi: 10.1053/j.gastro.2020.04.014. Epub 2020 Apr 12.
2
Evidence-based and mechanistic insights into exclusion diets for IBS.基于证据的和机制的见解,探讨用于 IBS 的排除饮食。
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):406-413. doi: 10.1038/s41575-020-0270-3. Epub 2020 Mar 2.
3
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review.炎症性肠病患者与非炎症性肠病患者的肠道微生物群差异:系统评价。
Gastroenterology. 2020 Mar;158(4):930-946.e1. doi: 10.1053/j.gastro.2019.11.294. Epub 2019 Dec 5.
4
Application of Machine Learning in Microbiology.机器学习在微生物学中的应用。
Front Microbiol. 2019 Apr 18;10:827. doi: 10.3389/fmicb.2019.00827. eCollection 2019.
5
A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome.非囊性纤维化支气管扩张气道微生物组的纵向特征。
Sci Rep. 2019 May 3;9(1):6871. doi: 10.1038/s41598-019-42862-y.
6
Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review.肠易激综合征患者的肠道微生物群:系统评价。
Gastroenterology. 2019 Jul;157(1):97-108. doi: 10.1053/j.gastro.2019.03.049. Epub 2019 Mar 30.
7
A Novel Sparse Compositional Technique Reveals Microbial Perturbations.一种新型稀疏合成技术揭示了微生物扰动。
mSystems. 2019 Feb 12;4(1). doi: 10.1128/mSystems.00016-19. eCollection 2019 Jan-Feb.
8
Microbial network disturbances in relapsing refractory Crohn's disease.复发缓解型和难治性克罗恩病中的微生物网络紊乱
Nat Med. 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z. Epub 2019 Jan 21.
9
Species-level functional profiling of metagenomes and metatranscriptomes.宏基因组和宏转录组的物种水平功能分析。
Nat Methods. 2018 Nov;15(11):962-968. doi: 10.1038/s41592-018-0176-y. Epub 2018 Oct 30.
10
Update on Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Disease.炎症性肠病患者粪便微生物群移植的最新进展
Gastroenterol Hepatol (N Y). 2018 May;14(5):319-322.

想象网络的行业交互队列(MAGIC)研究:炎症性肠病和肠易激综合征的前瞻性观察性多中心队列研究方案。

IMAGINE Network's ind nd ut nteractions ohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome.

机构信息

Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada

Medicine, University of Calgary, Calgary, Alberta, Canada.

出版信息

BMJ Open. 2020 Oct 21;10(10):e041733. doi: 10.1136/bmjopen-2020-041733.

DOI:10.1136/bmjopen-2020-041733
PMID:33087380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7580069/
Abstract

INTRODUCTION

Gut microbiome and diet may be important in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and comorbid psychiatric conditions, but the mechanisms are unclear. We will create a large cohort of patients with IBS, IBD and healthy controls, and follow them over time, collecting dietary and mental health information and biological samples, to assess their gastrointestinal (GI) and psychological symptoms in association with their diet, gut microbiome and metabolome.

METHODS AND ANALYSIS

This 5-year observational prospective cohort study is recruiting 8000 participants from 15 Canadian centres. Persons with IBS who are 13 years of age and older or IBD ≥5 years will be recruited. Healthy controls will be recruited from the general public and from friends or relatives of those with IBD or IBS who do not have GI symptoms. Participants answer surveys and provide blood, urine and stool samples annually. Surveys assess disease activity, quality of life, physical pain, lifestyle factors, psychological status and diet. The main outcomes evaluated will be the association between the diet, inflammatory, genetic, microbiome and metabolomic profiles in those with IBD and IBS compared with healthy controls using multivariate logistic regression. We will also compare these profiles in those with active versus quiescent disease and those with and without psychological comorbidity.

ETHICS AND DISSEMINATION

Approval has been obtained from the institutional review boards of all centres taking part in the study. We will develop evidence-based knowledge translation initiatives for patients, clinicians and policymakers to disseminate results to relevant stakeholders. NCT03131414.

摘要

简介

肠道微生物组和饮食可能在肠易激综合征(IBS)、炎症性肠病(IBD)和并存的精神疾病中起重要作用,但机制尚不清楚。我们将创建一个由大量 IBS、IBD 和健康对照患者组成的队列,并对他们进行随访,收集饮食和心理健康信息及生物样本,以评估他们的胃肠道(GI)和心理症状与他们的饮食、肠道微生物组和代谢组的关系。

方法和分析

这是一项为期 5 年的观察性前瞻性队列研究,正在从加拿大的 15 个中心招募 8000 名参与者。将招募年龄在 13 岁及以上的 IBS 患者或患病 5 年以上的 IBD 患者。健康对照者将从普通人群以及那些没有 GI 症状的 IBD 或 IBS 患者的朋友或亲戚中招募。参与者每年回答调查问题并提供血液、尿液和粪便样本。调查评估疾病活动度、生活质量、身体疼痛、生活方式因素、心理状态和饮食。使用多变量逻辑回归评估 IBD 和 IBS 患者与健康对照组之间饮食、炎症、遗传、微生物组和代谢组谱的主要结果。我们还将比较这些谱在活动期与缓解期疾病、有和无心理共病的患者之间的差异。

伦理和传播

所有参与研究的中心的机构审查委员会均已批准该研究。我们将为患者、临床医生和决策者制定循证知识转化计划,将研究结果传播给相关利益攸关方。NCT03131414。